IPS-Mehtalia
IPS-Integrated Project Services (IPS-Mehtalia) is a Berkshire Hathaway-owned engineering, project controls, and construction management firm founded in 1965, serving global pharmaceutical, biotech, and life sciences clients with cGMP-compliant facility design and delivery across the Americas, EMEA, APAC, and India.
- Company typePrivate
- Founded1965
- HeadquartersBlue Bell, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What IPS-Mehtalia does
IPS-Integrated Project Services, LLC, operating under the trade names IPS and IPS-Mehtalia, is a global technical consulting, engineering, project controls, and construction management firm headquartered in Blue Bell, Pennsylvania. Founded in 1965, the firm is a subsidiary of Berkshire Hathaway and employs between 1,001 and 5,000 people across the Americas (United States, Canada, Brazil), EMEA, APAC, and India. Its service offering is built around the design, expansion, and modernization of capital-intensive manufacturing facilities for the pharmaceutical, biotechnology, and life sciences industries, where cGMP compliance, validation, and process-engineering expertise are core deliverables.
The underlying service stack integrates feasibility and conceptual studies, detailed process and facility design, project controls and program management, and full construction management execution, enabling IPS to act as a single point of accountability from early engineering through commissioning. The firm's technology base is its accumulated regulatory know-how, validated delivery methodologies, and global engineering talent rather than a packaged software platform; the 2024 ESG Report indicates active investment in governance and sustainability positioning aligned with enterprise pharmaceutical buyer criteria.
The business model is project-based professional services, monetized through fee-for-service consulting, fixed-price engineering and construction management contracts, and likely master service agreements with multinational pharmaceutical and biotech clients. Customer segments are large and mid-cap pharmaceutical manufacturers, biotech firms, and life sciences companies undertaking greenfield, expansion, or modernization capex in regulated environments. Berkshire Hathaway ownership provides long-duration capital and strategic stability, supporting multi-year program commitments typical of the industry.
IPS-Mehtalia firmographics
Firmographics- Name
- IPS-Mehtalia
- Legal name
- IPS-Integrated Project Services, LLC
- Website
- https://mehtalia.com
- Company type
- Private
- Founded year
- 1965
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- IPS-Integrated Project Services (IPS-Mehtalia) is a Berkshire Hathaway-owned engineering, project controls, and construction management firm founded in 1965, serving global pharmaceutical, biotech, and life sciences clients with cGMP-compliant facility design and delivery across the Americas, EMEA, APAC, and India.
- Ownership category
- akta.pro rank
IPS-Mehtalia industry classification
Industry- Product category
- Pharmaceutical Engineering Services
- NAICS
- Facilities Support Services (56121)
- SIC
- Services-Facilities Support Management Services (8744)
- akta.pro primary industry
- Pest Management Services (IMAIAAAH)
Keywords
Where IPS-Mehtalia is headquartered
LocationHeadquarters
- HQ city
- Blue Bell
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
IPS-Mehtalia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Engineering and Project Services: IPS generates revenue through providing integrated project services including engineering design, construction management, validation, and operational support for life sciences facilities. Revenue is derived from professional services engagements with pharmaceutical and biotech companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
IPS-Mehtalia product offering
Product offeringCore offering
IPS-Mehtalia provides integrated project services for life sciences facilities, including engineering design, construction management, validation, and operational support. The firm delivers end-to-end project execution for pharmaceutical and biotech clients requiring GMP-compliant facilities, clean rooms, and production environments across Americas, EMEA, APAC, and India.
Product overview
IPS-Integrated Project Services, LLC is a professional services company that provides integrated project services across multiple industries. The company offers expertise services, facility design, and project management solutions. Based on the website structure, IPS operates as a services firm rather than a software product company, providing consulting and project execution services rather than discrete software products or modules.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated Engineering and Project Services
Companies that use IPS-Mehtalia
Customer profileSegments2 records
Ideal customer profiles2 records
IPS-Mehtalia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
IPS-Mehtalia partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
IPS-Mehtalia competitors and assessment
Company assessmentDirect peers
- CRB: CRB is a direct competitor to IPS in life sciences engineering, architecture, and construction services. It focuses on advanced technology, biotech, and pharmaceutical facility design and delivery, making it the most closely comparable peer in the regulated life sciences engineering space.
Broad incumbents
- Stantec: Stantec is a global engineering, architecture, and environmental services firm with a buildings and life sciences practice. It competes with IPS on pharmaceutical and biotech facility design and project management as part of a broader portfolio including water, infrastructure, and energy.
- AECOM: AECOM is a global infrastructure consulting firm with a life sciences and industrial facilities practice that overlaps with IPS's pharma/biotech work. It competes on regulated facility design and program management but operates at much larger scale across transportation, water, and environmental markets.
- Bechtel: Bechtel is a premier global engineering, construction, and project management firm with a life sciences and industrial facilities capability. It is a comparable broad incumbent on mega-scale pharmaceutical capital projects but is substantially larger and more diversified across energy, defense, and infrastructure.
- Wood Group: Wood is a global engineering and consulting firm with life sciences and pharmaceutical capabilities alongside its dominant energy and industrial businesses. It is a broad incumbent comparable to IPS on regulated facility projects, though its pharma exposure is far smaller than IPS's focus.
- Jacobs Solutions: Jacobs is a large global engineering, technical, and professional services firm with a significant life sciences and advanced facilities practice. It competes with IPS on pharma/biotech capital projects but as part of a much broader portfolio spanning critical infrastructure, water, and national security.
- Arcadis: Arcadis is a global design, engineering, and consulting firm with expertise in life sciences facilities among other sectors. It is a broad incumbent comparable to IPS for pharma/biotech facility design and project management engagements, though life sciences is a smaller portion of its overall portfolio.
- WSP Global: WSP is a global engineering professional services consultancy with property and buildings practices that include life sciences work. It is comparable to IPS as a diversified engineering services peer pursuing regulated facility projects, though its life sciences exposure is one of many segments.
- Fluor Corporation: Fluor is a global engineering, procurement, fabrication, construction, and project management firm with a Life Sciences and Advanced Technologies business line. It competes with IPS on large pharmaceutical and biotech facility projects but is far more diversified across energy, mining, and industrial markets.
Emerging players
- Burns & McDonnell: Burns & McDonnell is an employee-owned engineering, architecture, and construction firm with growing life sciences capabilities. It is comparable to IPS as a full-service engineering firm pursuing pharmaceutical and biotech facility work, though its life sciences practice is less established than IPS's and represents an emerging rather than core focus area.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
IPS-Mehtalia social profiles
Digital presenceIPS-Mehtalia financial estimates
Financial estimateRevenue estimate
Valuation estimate
IPS-Mehtalia leadership team
Management profileNumber of profiles
IPS-Mehtalia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IPS-Mehtalia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IPS-Mehtalia
What does IPS-Mehtalia do?
IPS-Mehtalia provides integrated project services for life sciences facilities, including engineering design, construction management, validation, and operational support. The firm delivers end-to-end project execution for pharmaceutical and biotech clients requiring GMP-compliant facilities, clean rooms, and production environments across Americas, EMEA, APAC, and India.
Is IPS-Mehtalia a public or private company?
IPS-Mehtalia is a private company. It is classified as corporate owned and is currently operating.
When was IPS-Mehtalia founded?
IPS-Mehtalia was founded in 1965. It employs 1,001 to 5,000 people.
Where is IPS-Mehtalia based?
IPS-Mehtalia is headquartered in Blue Bell, United States, in the North America region.
How does IPS-Mehtalia make money?
One revenue line is on record: engineering and Project Services.
Who are IPS-Mehtalia's main competitors?
CRB is listed as a direct peer. Broad incumbents are Stantec, AECOM, Bechtel, Wood Group, Jacobs Solutions, Arcadis, WSP Global and Fluor Corporation. Burns & McDonnell is listed as an emerging player.
Does IPS-Mehtalia have an API?
No public API is recorded for IPS-Mehtalia.
What industry is IPS-Mehtalia in?
IPS-Mehtalia's product category is Pharmaceutical Engineering Services. Its primary akta.pro industry code is IMAIAAAH, Pest Management Services. Its NAICS code is 56121 and its SIC code is 8744.